BK261315- ELUclear Elution Kit
The FDA has acknowledged the ELUclear Elution Kit, a product designed to remove antibodies bound to red cell antigens using a controlled dissociation process.
This affects laboratory professionals in transfusion medicine, blood bank quality managers, and manufacturers of antibody elution systems.
The use of a controlled dissociation process for removing antibodies is critical for accurate blood typing and cross-matching operations. This update indicates a specific technical approach (dissociation) for antibody removal that regulatory departments must ensure is properly integrated into their current laboratory compliance frameworks.
Regulatory and QA teams should ensure that standard operating procedures for antibody dissociation reflect the specifications of the ELUclear Elution Kit and that laboratory staff are trained on this controlled dissociation process. Verification of validation documentation for red cell antigen processing is advised.
The ELUclear Elution Kit removes antibodies bound to red cell antigens through a controlled dissociated process.
Open in openFDA / FDA.gov